Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.

Abstract:

:This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from multiple myeloma (MM), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) All of them were in remission after chemotherapy or radiotherapy. Our results indicated that IL-2 given subcutaneously at a low dose of 100 microg/day for 3 weeks induced IFN-gamma and TNF-alpha in plasma (measured 24 hrs after the last dose of IL-2) and affected the ability of blood leukocytes to produce cytokines. Production of IFN-gamma induced in vitro with PHA was enhanced, but TNF-alpha production induced by lipopolysaccharide (LPS) and virus (Newcastle Disease Virus) was depressed. The expression of both: surface IL-2R, especially beta subunit on total population of lymphocytes and NK cells, and soluble form of IL-2R, of chain were significantly enhanced after low-dose IL-2 therapy. Low dose IL-2 therapy was well tolerated by all patients, and side effects not exceeding II grade of toxicity according to WHO scale were observed. Five patients with MM relapsed 3-10 month after cessation of IL-2 therapy, but all patients with Hodgkin's and non-Hodgkin's lymphomas are still in remission (20 months of observation).

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

doi

10.3109/10428199909145740

keywords:

subject

Has Abstract

pub_date

1999-10-01 00:00:00

pages

355-66

issue

3-4

eissn

1042-8194

issn

1029-2403

journal_volume

35

pub_type

杂志文章
  • Tryptase a novel biochemical marker of acute myeloid leukemia.

    abstract::Despite maturation arrest, blast cells in acute myeloid leukemia (AML) are often capable of expressing lineage-restricted (granulomonocytic or myelomastocytic) differentiation antigens. Tryptases are lineage-associated serine proteases primarily expressed in mast cells, and less abundantly in blood basophils. We have ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000039965

    authors: Sperr WR,Hauswirth AW,Valent P

    更新日期:2002-12-01 00:00:00

  • Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.

    abstract::In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation r...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428194.2010.547155

    authors: Wirth A,Grigg A,Wolf M,Goldstein D,Johnson C,Davis S,Dutu G,Kypreos P,Smith C,Kneebone A,Herzberg M,Joseph D,Catalano J,Roos D,Stone J,Reynolds J

    更新日期:2011-05-01 00:00:00

  • Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

    abstract::This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049659

    authors: Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

    更新日期:1994-06-01 00:00:00

  • Bisantrene in relapsed and refractory acute myelogenous leukemia.

    abstract::Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinica...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309147373

    authors: Spadea A,Petti MC,Aloespiriti MA,Avvisati G,De Gregoris C,Fazi P,Latagliata R,Amadori S,Mandelli F

    更新日期:1993-02-01 00:00:00

  • Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.

    abstract::Whole-blood three-color immunofluorescence analysis was used to investigate the role of CD5/CD72 and CD21/CD23 receptor-ligand pair formation on B-chronic lymphocytic leukemia (B-CLL) cells as well as sCD23 and bcl-2 oncoprotein expression in disease progression and activity and total tumor mass in B-cell chronic leuk...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709114169

    authors: Gagro A,Dasić G,Sabioncello A,Rabatić S,Reckzeh B,Havemann K,Kardum I,Jacksić B,Vitale B

    更新日期:1997-04-01 00:00:00

  • Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

    abstract::Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.762978

    authors: Ram R,Storb R

    更新日期:2013-08-01 00:00:00

  • Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.

    abstract::Survival of chronic lymphocytic leukemia (CLL) cells in vivo is supported by the tissue microenvironment, which includes components of the extracellular matrix. Interactions between tumor cells and the extracellular matrix are in part mediated by CD44, whose principal ligand is hyaluronic acid. Here, we show that CD44...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.569962

    authors: Herishanu Y,Gibellini F,Njuguna N,Hazan-Halevy I,Farooqui M,Bern S,Keyvanfar K,Lee E,Wilson W,Wiestner A

    更新日期:2011-09-01 00:00:00

  • tp53-dependent G2 arrest mediator candidate gene, Reprimo, is down-regulated by promoter hypermethylation in pediatric acute myeloid leukemia.

    abstract::Reprimo (RPRM) is a novel tumor suppressor. However, the expression and molecular function of RPRM in pediatric acute myeloid leukemia (AML) is still unknown. We observed hypermethylation of the RPRM promoter in 8/11 leukemia cell lines and in 44.8% (47/105) of pediatric AML samples compared with 6.7% (2/30) of contro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1011157

    authors: Tao YF,Li ZH,Wang NN,Fang F,Xu LX,Pan J

    更新日期:2015-01-01 00:00:00

  • Interferon-gamma and human megakaryopoiesis.

    abstract::Interferon-gamma (IFN-gamma) exhibits various properties including antigrowth activity in neoplastic and normal cells and regulatory roles in immune responses and hematopoiesis, but studies of IFN-gamma effects on human megakaryopoiesis have been inconclusive. Recently we have used serum-free culture of purified CD34+...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057590

    authors: Tsuji K,Muraoka K,Nakahata T

    更新日期:1998-09-01 00:00:00

  • Induced apoptosis by mild hyperthermia occurs via telomerase inhibition on the three human myeloid leukemia cell lines: TF-1, K562, and HL-60.

    abstract::The purpose of this research was to understand the effect of hyperthermia on the telomerase activity in human leukemic cell lines (HL-60, K562, and TF-1). The cells were treated by hyperthermia at the range of 41-44 degrees C for 120 min and incubated for 96 h. Then telomerase activity, cell proliferation, and apoptos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190903129130

    authors: Deezagi A,Manteghi S,Khosravani P,Vaseli-Hagh N,Soheili ZS

    更新日期:2009-09-01 00:00:00

  • Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.

    abstract::Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2086 MDS patients diagnosed in 2004-13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle after 2005. We used multivariate l...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1663423

    authors: Zeidan AM,Hu X,Zhu W,Stahl M,Wang R,Huntington SF,Giri S,Bewersdorf JP,Podoltsev NA,Gore SD,Ma X,Davidoff AJ

    更新日期:2020-02-01 00:00:00

  • Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.

    abstract::Relapse represents the main cause of treatment failure after allogeneic stem cell transplant (allo-SCT). The detection of minimal residual disease (MRD) by multiparametric flow cytometry (MFC), chimerism, cytogenetics and molecular analysis may be critical to prevent relapse. Therefore, we assessed the overall agreeme...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.789508

    authors: Rossi G,Carella AM,Minervini MM,Savino L,Fontana A,Pellegrini F,Greco MM,Merla E,Quarta G,Loseto G,Capalbo S,Palumbo G,Cascavilla N

    更新日期:2013-12-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006260

    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00

  • Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia.

    abstract::Dysregulation of MYBL2 has been associated to tumorigenesis and the S427G polymorphism could induce partial inactivation of MYBL2, associating it with cancer risk. It has previously been shown that MYBL2 was over-expressed in some acute myeloid leukemias (AML), portending poor prognosis. However, to date no studies ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1049167

    authors: Dolz S,García P,Llop M,Fuster Ó,Luna I,Ibáñez M,Gómez I,López M,Such E,Cervera J,Sanz MA,De Juan I,Palanca S,Murria R,Bolufer P,Barragán E

    更新日期:2016-02-01 00:00:00

  • Bone marrow transplantation in hemophagocytic lymphohistiocytosis.

    abstract::Two important syndromes of hemophagocytic lymphohistiocytosis (HLH) have to be considered in infants and young children with recurrent fever, organomegaly and cytopenias. Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infil...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057957

    authors: Dürken M,Finckenstein FG,Janka GE

    更新日期:2001-03-01 00:00:00

  • The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).

    abstract::The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428140310001616935

    authors: Bischof Delaloye A

    更新日期:2003-01-01 00:00:00

  • Radiotherapy in early stage Hodgkin's disease.

    abstract::Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409056292

    authors: Zinzani PL,Barbieri E,Gherlinzoni F,Frezza G,Mazza P,Pica A,Ammendolia I,Bendandi M,Neri S,Miniaci G

    更新日期:1994-04-01 00:00:00

  • Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia.

    abstract::The single nucleotide polymorphism (SNP) rs16754 of the WT1 gene has been described as a possible prognostic marker in patients with acute myeloid leukemia (AML). However, the results in this field are not reproducible in different cohorts. In this study, we investigated WT1 mutations, expression levels and SNP rs1675...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.791985

    authors: Luo S,Yu K,Yan QX,Shen ZJ,Wu JB,Chen HM,Gao SM

    更新日期:2014-02-01 00:00:00

  • Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

    abstract::There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.555892

    authors: Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

    更新日期:2011-05-01 00:00:00

  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

    abstract::Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/1042819031000063462

    authors: George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

    更新日期:2003-10-01 00:00:00

  • Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.

    abstract::Murine monoclonal antibody (mAb) 7C11 binds to the same cell surface epitope as anti-APO-1 and anti-Fas and reacts specifically with cells transfected with a cDNA encoding the human Fas antigen. Furthermore, incubation with 7C11 causes death of hematopoietic cell lines that express APO-1/Fas but not APO-1/Fas-negative...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509051703

    authors: Robertson MJ,Manley TJ,Pichert G,Cameron C,Cochran KJ,Levine H,Ritz J

    更新日期:1995-03-01 00:00:00

  • Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia.

    abstract::The NK-like family of homeobox genes includes TLX1, TLX3 and NKX2-5, which are ectopically activated in distinct subsets of T-cell acute lymphoblastic leukemia (T-ALL) cells. Here we analysed their effect on the miR-17-92 cluster overexpressed in several types of cancer, including T-ALL. The pri-miR-17-92 polycistron ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802626632

    authors: Nagel S,Venturini L,Przybylski GK,Grabarczyk P,Schmidt CA,Meyer C,Drexler HG,Macleod RA,Scherr M

    更新日期:2009-01-01 00:00:00

  • Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis.

    abstract::Natural killer (NK) cells provide anti-infectious, anti-neoplastic, and immunomodulatory function effected by both cytokine production and direct cellular cytotoxicity that is not major histocompatibility complex-restricted. NK cells lack truly specific cell surface determinants as well as antigen-specific receptors. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057982

    authors: Morice WG,Leibson PJ,Tefferi A

    更新日期:2001-04-01 00:00:00

  • Hepatitis C virus, B-cell proliferation and lymphomas.

    abstract::Accumulating evidence support a role for hepatitis C virus (HCV) in the pathogenesis of human lymphoproliferative disorders. Clonal expansions of B lymphocytes have been prevalently detected in the bone marrow, in the liver and in the peripheral blood of HCV-infected patients. Epidemiologic studies have associated HCV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290016845

    authors: Gasparotto D,De Re V,Boiocchi M

    更新日期:2002-04-01 00:00:00

  • Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.

    abstract::The classification of germinal centre (GC) and non-GC is an important prognostic immunophenotype for patients with diffuse large B cell lymphoma (DLBCL) following anthracycline-based chemotherapy. The expression of the anti-apoptotic protein, Bcl-2, has been associated with an unfavourable prognosis in patients with D...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802626616

    authors: Song MK,Chung JS,Shin DH,Seol YM,Shin HJ,Choi YJ,Cho GJ

    更新日期:2009-01-01 00:00:00

  • TP53 mutations in myelodysplastic syndrome.

    abstract::Mutations of the TP53 tumor suppressor gene, contributing to the development and progression of a wide variety of human malignancies, are found in some of the patients with myelodysplastic syndromes (MDS). Previous reports revealed that TP53 mutations were found in 0-25% of patients with MDS and are closely associated...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609054848

    authors: Misawa S,Horiike S

    更新日期:1996-11-01 00:00:00

  • Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.

    abstract::We performed three different studies to obtain additional data on the biological and prognostic role of vascular endothelial growth factor C (VEGFC) in classical Hodgkin lymphoma (cHL): (1) serum VEGFC levels were measured by enzyme-linked immunosorbent assay in 80 patients; (2) immunohistochemical VEGFC expression in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.952227

    authors: Rueda A,Olmos D,Vicioso L,Quero C,Gallego E,Pajares-Hachero BI,Mendiola M,Casanova M,Álvarez M,Provencio M,Alba E

    更新日期:2015-05-01 00:00:00

  • Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.

    abstract::Non-malignant host immune cells are the main substrate in classical Hodgkin lymphoma (HL) microenvironment. Reconstitution of lymphocyte populations following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) can support tumor growth in HL patients. We investigated re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1581934

    authors: Batorov EV,Pronkina NV,Tikhonova MA,Kryuchkova IV,Sergeevicheva VV,Sizikova SA,Ushakova GY,Aristova TA,Batorova DS,Shishkova IV,Gilevich AV,Shevela EY,Ostanin AA,Chernykh ER

    更新日期:2019-10-01 00:00:00

  • Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center.

    abstract::We investigated 41 diffuse large B-cell lymphomas (DLBCL) diagnosed at one center harboring ≥50% of latently Epstein-Barr virus (EBV)-infected neoplastic cells occurring in 34 patients aged ≥50 years and in 7 patients younger than 50 years in the absence of any known immunodeficiency for the expression patterns of EBV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1169406

    authors: Jöhrens K,Trappe RU,Lenze D,Pfreundschuh M,Ziepert M,Hummel M,Anagnostopoulos I

    更新日期:2016-12-01 00:00:00

  • Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.

    abstract::The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009059268

    authors: Masdehors P,Merle-Béral H,Magdelénat H,Delic J

    更新日期:2000-08-01 00:00:00